Aid for technical support personnel call 2023 of the State Research Agency
November 26, 2023XVIII Call for AMA Foundation Scholarships 2023-2024
November 28, 2023Experimented in mice, this 'double attack' strategy against triple negative cancer prevents the disease from progressing and 'significantly' reduces the tumor
"It opens up an exciting therapeutic avenue that could transform this cancer into a controllable disease," the authors point out.
Two blows in one against the worst breast cancer. Researchers of the Center for Genomic Regulation (CRG) and Vall d'Hebron Institute of Oncology (VHIO) of Barcelona have shown that the simultaneous inhibition of two different proteins can represent a new effective strategy to combat triple negative breast cancer, the one with the worst prognosis due to its aggressiveness and resistance to drugs. The research, which is published today in the journal 'EMBO Molecular Medicine', "It opens up an exciting therapeutic avenue that could transform triple-negative breast cancer into a controllable disease," the CRG postdoctoral researcher told ABC. Laura Pascual Reguant, first author of the article.
Breast cancer is the most diagnosed type of cancer and the fourth most common cause of cancer-related death in women, with more than two million cases worldwide and 685.000 deaths in 2020. 15 percent of these cases are triple negative breast cancer. Its prognosis is poor since the disease is highly resistant to existing treatments because its cells, unlike hormonal tumors, lack the receptors targeted by breast cancer drugs.
The new research, experimented on mice, shows that attacking two proteins involved in the proliferation of the disease at the same time significantly reduces the tumor. «We have experimented with it in mice but it has been seen that it prevents the disease from progressing and that is important as point with a view to future control of the disease," says Pascual.
Source: ABC Daily